Group B Meningococcal Recombinant Protein Vaccine

Neisseria meningitidis (meningococcus) is a gram-negative bacterial pathogen that can cause meningitis with a high mortality rate. There are over 12 serogroups of meningococcus based on their polysaccharide capsule, while six are responsible for most diseases. Researchers have found that the polysaccharide capsules of serogroups A, C, W135, and Y are immunogenic, and vaccines made from purified polysaccharides extracted from the pathogenic bacteria are widely used globally, including in China, the United States, and Europe.

?

The polysaccharide capsule of Meningococcal serogroup B（MenB）does not have immunogenicity, so the development of its vaccine primarily relies on outer membrane vesicle (OMV) and recombinant protein (rProtein) vaccines. Pfizer's Trumenba (rLP2086) and GSK's Bexsero (MenB-4C), based on rProtein technology, have been approved for use in most regions worldwide.

?

Trumenba, a recombinant protein vaccine developed and submitted by Pfizer's subsidiary Wyeth, is derived from the expression system of Escherichia coli (E. coli). The recombinant antigens in Trumenba are derived from two variants of factor H binding proteins (fHbp), namely A05 from the A family and B01 from the B family of MenB. Trumenba is a bivalent vaccine that utilizes these two variant proteins to enhance vaccine coverage.

?

The Bexsero vaccine was initially developed by Novartis and later transferred to GSK. Bexsero consists of four main components: recombinant fHbp (expressed in?E. coli), recombinant NadA (expressed in?E. coli), recombinant NHBA (expressed in?E. coli), and OMV (extracted from MenB). The rProtein components in Bexsero are either full-length proteins or fusion proteins.

?

Currently, no vaccines are available on the market in China for MenB. Green Bamboo, a subsidiary of Zhifei Biological, has independently developed a recombinant MenB vaccine (expressed in?E. coli). It is the first domestically approved MenB vaccine to enter the clinical phase.

?

Yaohai Bio-Pharma, leveraging years of experience in microbial expression systems (E. coli, yeast), provides CDMO services for developing and producing GMP rProtein vaccines. We have a proven track record of successfully delivering multiple projects for the development and production of recombinant subunit vaccines and VLP vaccines. With our extensive CDMO service experience, short delivery cycles, and commitment to high-quality products, Yaohai Bio-Pharma has established a comprehensive CMC service system to expedite the market entry for a wide range of customers' rProtein vaccine pipelines.

*?Recombinant NadA: Recombinant Neisseria Adhesin A

*?Recombinant NHBA: Recombinant Neisseria Heparin Binding Antigens

We are also actively seeking institutional or individual global partners; we offer the most competitive compensation in the industry. If you have any questions, please do not hesitate to contact us: [email protected]

?

For more details about Yaohai Bio-Pharma, kindly refer to:

https://www.yaohai-bio.com.cn/downloadfile?

?